Day: August 3, 2020

DURHAM, N.C., Aug. 03, 2020 (GLOBE NEWSWIRE) — Chimerix (NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, today announced that it will host a live conference call and audio webcast on Monday, August 10, 2020 at 8:30 a.m. ET to report financial results for the second quarter ended June 30, 2020, and to provide a business overview.To access the live conference call, please dial (877) 354-4056 (domestic) or (678) 809-1043 (international) at least five minutes prior to the start time, and refer to conference ID 3334648. A live audio webcast of the call will also be available on the Investors’ section of the Company’s website, www.chimerix.com. An archived webcast will be available on the Chimerix website approximately two hours after the...

ISELIN, N.J., Aug. 03, 2020 (GLOBE NEWSWIRE) — Provident Financial Services, Inc. (NYSE: PFS) (“Provident”), the parent company of Provident Bank, announced today that the acquisition of SB One Bancorp (Nasdaq: SBBX) (“SB One”) and its subsidiary, SB One Bank, closed effective July 31, 2020.Under the terms of the merger agreement, each outstanding share of SB One common stock will be exchanged for 1.357 shares of Provident common stock together with cash in lieu of any fractional shares. The combined organization will have approximately $12 billion in assets and will rank as the 3rd largest bank headquartered in New Jersey. The merger brings together two high-performing companies with complementary geographies and business lines.“We welcome the customers, employees, and shareholders of SB One to the Provident team. We also welcome...

TEL AVIV, Israel, Aug. 03, 2020 (GLOBE NEWSWIRE) — VBL Therapeutics (Nasdaq: VBLT), a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class treatments for cancer, today announced that it will host a conference call and live audio webcast on Thursday, August 13, 2020 at 8:30am Eastern Time to report second quarter ended June 30, 2020 financial results and to provide a corporate update.About VBLVascular Biogenics Ltd., operating as VBL Therapeutics, is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class treatments for cancer. VBL’s lead oncology product candidate, ofranergene obadenovec (VB-111), is a first-in-class, targeted anti-cancer gene-therapy agent that is being developed to treat a wide range of...

SECAUCUS, N.J., Aug. 03, 2020 (GLOBE NEWSWIRE) — Freshpet, Inc. (“Freshpet” or the “Company”) (NASDAQ: FRPT) announced the appointment of Thembi Machaba as Senior Vice President of Human Resources, effective August 1, 2020. Ms. Machaba will lead Freshpet’s Human Resources organization and report directly to Billy Cyr, Chief Executive Officer. “We are excited to welcome Thembi to the Freshpet team as an integral human resources leader that will position our Company for continued long-term growth,” commented Billy Cyr, Freshpet’s Chief Executive Officer. “Thembi has a demonstrated track record of leading diverse teams of professionals to new levels of success in a variety of highly competitive industries and fast-paced environments around the world. Her experience and energy are a valuable addition to our leadership team and we look...

WOODCLIFF LAKE, N.J., Aug. 03, 2020 (GLOBE NEWSWIRE) — PowerFleet, Inc. (Nasdaq: PWFL), a global leader and provider of subscription-based wireless IoT and M2M solutions for securing, controlling, tracking, and managing high-value enterprise assets, announced it will be outfitting a large portion of the full Day & Ross trailer fleet with PowerFleet’s LV-500 solar tracking solution and the PowerFleet LV-710 Freight Camera.As one of the largest transportation companies in Canada, with more than 8,000 employees, drivers, and owner operators, Day & Ross has grown to be a critical player in transportation and logistics in North America. With a focus on efficient and effective equipment utilization, Day & Ross intends on deploying the PowerFleet’s LV-500 product across a fleet of over 3,000 trailers to optimize the management...

BOSTON, Aug. 03, 2020 (GLOBE NEWSWIRE) — Akouos, Inc. (“Akouos”) (NASDAQ: AKUS), a precision genetic medicine company dedicated to developing potential gene therapies for people worldwide who live with disabling hearing loss, today announced that Manny Simons, Ph.D., M.B.A., CEO, President and co-founder, will participate in a fireside chat at the BTIG Virtual Biotechnology Conference on Monday, August 10 at 10:30 a.m. ET.A live webcast of the fireside chat will be accessible through the investors section of the company’s website at www.akouos.com. To access the webcast, please go on to the Akouos website approximately 15 minutes prior to the start time to ensure adequate time for any software downloads that may be required. A replay of the webcast will be available on Akouos’ website for 14 days following the conference.About AkouosAkouos...

BURLINGTON, Mass., Aug. 03, 2020 (GLOBE NEWSWIRE) — Cerence Inc. (NASDAQ: CRNC), AI for a world in motion, today announced Cerence Reader, a new product based on its neural text-to-speech (TTS) offerings – the most advanced TTS available today – that brings a natural, expressive voice into the car to read the news to drivers on the go.To hear this release read by Cerence Reader, visit https://youtu.be/M3nnyb-bFho.Cerence Reader leverages advances in AI and processing hardware to bring unprecedented levels of human-like speech to the car. Nearly indistinguishable from a human voice, Cerence Reader features long-form reading capabilities, including natural pausing and breathing, and automatic prediction of the appropriate reading style and emotional tone based on content, context, and category of news, including current events, sports,...

— Appointed David Meeker, M.D., as President and Chief Executive Officer –— FDA granted rare pediatric disease designations for setmelanotide for the treatment of POMC and LEPR deficiency obesities —— Submitted MAA to EMA for setmelanotide in POMC and LEPR deficiency obesities —— Received FDA acceptance of NDA for setmelanotide for POMC and LEPR deficiency obesities for filing; assigned PDUFA goal date of November 27, 2020 –— On track to announce topline data from pivotal Phase 3 trial of setmelanotide in BBS and Alström syndrome in fourth quarter of 2020 or early in the first quarter of 2021 —BOSTON, Aug. 03, 2020 (GLOBE NEWSWIRE) — Rhythm Pharmaceuticals, Inc. (Nasdaq:RYTM), a late-stage biopharmaceutical company aimed at developing and commercializing therapies for the treatment...

Tucows to provide technology platform to support DISH WirelessDISH acquires customer relationships and related Ting Mobile assetsTORONTO and ENGLEWOOD, Colo., Aug. 03, 2020 (GLOBE NEWSWIRE) — DISH Network Corporation (NASDAQ: DISH) and Tucows Inc. (NASDAQ: TCX, TSX: TC) today announced that DISH has chosen Tucows as a technology partner for its retail wireless business. With a history of digital innovation, Tucows has made the strategic decision to offer Mobile Services Enabler (MSE) solutions, beginning with DISH. As part of this agreement, DISH has also acquired Ting Mobile assets, including customer relationships.Effective August 1, 2020, most Ting Mobile customers across the U.S. became customers of DISH. These customers will continue to use their current phones and will enjoy the same rates and excellent customer experience....

SAN DIEGO, Aug. 03, 2020 (GLOBE NEWSWIRE) — Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced an exclusive license agreement with KYORIN Pharmaceutical Co., Ltd. (“Kyorin”) that provides Otonomy with exclusive worldwide rights to develop, manufacture and commercialize a novel compound for the treatment of sensorineural hearing loss. Under the terms of the agreement, Otonomy will make an upfront payment to Kyorin as well as success-based milestone payments and royalties on worldwide net sales of a product containing the patent-protected compound. Otonomy is formulating the compound utilizing the company’s proprietary technology to provide sustained drug exposure in the inner ear following a single local administration.“We are pleased...